ORPHA:2030
Fibrosarcoma
Publications
53,665
Trials
34
Interventional, condition-specific
Researchers
1,339
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005164
- MeSH:D005354
- UMLS:C0016057
- NCIT:C3043
Additional Mondo synonyms (6)
fibrosarcoma · fibrosarcoma (disease) · fibrosarcoma (excluding infantile fibrosarcoma) · fibrosarcoma - not infantile · fibrosarcoma, malignant · malignant fibromatous neoplasm
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
53,665 matched papers (22,637 in last 10 years) Source
- Phenotype characterisedPresent
9 HPO annotations (e.g. Subcutaneous nodule; Fibrosarcoma; Pain) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
34 matched on ClinicalTrials.gov (8 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
9
Associated phenotypes · MONDO:0005164
- Subcutaneous nodule
- Fibrosarcoma
- Pain
- Lymphadenopathy
- Thickened skin
Showing 5 of 9 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
14
Drugs / clinical candidates · MONDO_0005164
- CYCLOPHOSPHAMIDE·phase 2
- DACTINOMYCIN·phase 2
- ETOPOSIDE·phase 2
- IFOSFAMIDE·phase 2
- IMATINIB MESYLATE·phase 2
- LAROTRECTINIB·phase 2
- PELAREOREP·phase 2
- SUNITINIB MALATE·phase 2
- VINCRISTINE·phase 2
- DOCETAXEL·phase 1
- LB-100·phase 1
- CISPLATIN·unknown
- LORNOXICAM·unknown
- REGORAFENIB·unknown
CTD chemicals (MyDisease.info)
18 associated chemicals · 57 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Arsenic Trioxide · therapeutic
- Carrageenan · therapeutic
- Cisplatin · therapeutic
- Dexamethasone · therapeutic
- Indomethacin · therapeutic
- mangiferin · therapeutic
- VADIC protocol · therapeutic
- 1,8-dinitropyrene · marker/mechanism
- 2-nitrotoluene · marker/mechanism
- dibenzo(a,h)pyrene · marker/mechanism
- dibenzo(a,i)pyrene · marker/mechanism
- dibenzo(a,l)pyrene · marker/mechanism
Pathways: EGFR tyrosine kinase inhibitor resistance; MAPK signaling pathway; Ras signaling pathway; IRS-mediated signalling; SOS-mediated signalling; Developmental Biology; Cytokine Signaling in Immune system; Signaling by SCF-KIT
Literature
Is anyone studying this?
53,665
53,665 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
53,665 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
22,637 in the last 10 years · low confidence
Phrase hits: 53,665 · MeSH hits: 0
Who's working on it?
1,339
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang Y6 papers · 2026
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China. wangyvmin@csu.edu.cn.
Papers in Europe PMC - 02Kim MM5 papers · 2026
Department of Cosmetics Engineering, and Graduate School of Applied Chemistry·Food Engineering, Dong-Eui University, Busan, Republic of Korea. mmkim@deu.ac.kr.
Papers in Europe PMC - 03Liu Y5 papers · 2026
Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Papers in Europe PMC - 04Chen Y4 papers · 2026
Department of Urology, Institute of Precision Drug Innovation and Cancer Center, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Papers in Europe PMC - 05Jiang Y4 papers · 2026
TCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Papers in Europe PMC - 06Li W4 papers · 2026
Department of Cardiovascular Surgery, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Papers in Europe PMC - 07Li Z4 papers · 2026
Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Papers in Europe PMC - 08Wang J4 papers · 2026
Department of Musculoskeletal Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Papers in Europe PMC - 09Wang S4 papers · 2026
Department of General Surgery, Peking University First Hospital, Peking University, Beijing, China.
Papers in Europe PMC - 10Zhang W4 papers · 2026
Department of Orthopedic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
34
interventional trials for this specific condition
34 interventional trials matched this specific condition name; 8 currently recruiting in our sample.
Data as of 11 September 2026
34 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.3th percentile).
low confidence · 96.3th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
34 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06849986·RECRUITING·IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Not reviewed·Conditions: Soft Tissue Sarcomas · Angiosarcoma · Fibrosarcoma · Leiomyosarcoma·Matched via name phrase
- NCT06239272·RECRUITING·NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Not reviewed·Conditions: Adipocytic Neoplasm · Liposarcoma · Atypical Fibroxanthoma · Angiomatoid Fibrous Histiocytoma·Matched via name phrase
- NCT06638931·RECRUITING·Agnostic Therapy in Rare Solid Tumors
Not reviewed·Conditions: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Angiosarcoma·Matched via name phrase
- NCT06526897·NOT YET RECRUITING·Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
Not reviewed·Conditions: Adult Pleomorphic Rhabdomyosarcoma · AJCC Grade 2 Sarcoma · AJCC Grade 3 Sarcoma · Alveolar Soft Part Sarcoma·Matched via name phrase
- NCT06387485·RECRUITING·A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
Not reviewed·Conditions: Sarcoma, Ewing · Chondrosarcoma · Osteosarcoma · Fibrous Histiocytoma·Matched via name phrase
- NCT03967834·RECRUITING·Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Not reviewed·Conditions: Soft Tissue Sarcoma · Clear Cell Sarcoma · Epithelioid Sarcoma · Perivascular Epithelioid Cell Neoplasms·Matched via name phrase
- NCT06277154·RECRUITING·MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Not reviewed·Conditions: Leiomyosarcoma · Liposarcoma · Synovial Sarcoma · Angiosarcoma·Matched via name phrase
- NCT05525273·RECRUITING·Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma
Not reviewed·Conditions: Craniopharyngioma·Matched via name phrase
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05515068·NOT YET RECRUITING·Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Not reviewed·Conditions: Osteosarcoma · Bone Tumor · Bone Sarcoma · High Grade Sarcoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (2)
- ctis·2024-516392-33-00·Authorised, ongoing·Phase III study comparing Trabectedin (T) versus T plus tTF-NGR to entrap T inside the tumor in patients with metastatic and/or refractory soft tissue sarcoma (STS), Acronym: TRABTRAP
skipped — LLM skipped (--skip-llm)
- ctis·2024-510877-67-00·Cancelled·Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Fibrosarcoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Fibrosarcoma" OR "fibrosarcoma (disease)" OR "fibrosarcoma (excluding infantile fibrosarcoma)" OR "fibrosarcoma - not infantile" OR "fibrosarcoma, malignant" OR "malignant fibromatous neoplasm"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Fibrosarcoma" OR "fibrosarcoma (disease)" OR "fibrosarcoma (excluding infantile fibrosarcoma)" OR "fibrosarcoma - not infantile" OR "fibrosarcoma, malignant" OR "malignant fibromatous neoplasm"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 34 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (53665) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T18:49:09.910Z
